The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Vaccines for the 21st Century: A Tool for Decisionmaking
Table A24–1 Incidence Rate for Noninvasive and Invasive Group A Streptococcus Infections
Age Groups
Population
Incidence Rates (per 100,000)
Cases
NONINVASIVE INFECTIONS
<1
3,963,000
1,009.34
40,000
1–4
16,219,000
2,466.24
400,000
5–14
38,056,000
8,408.66
3,200,000
15–24
36,263,000
992.75
360,000
25–34
41,670,000
0.00
0
35–44
42,149,000
0.00
0
45–54
30,224,000
0.00
0
55–64
21,241,000
0.00
0
65–74
18,964,000
0.00
0
75–84
11,088,000
0.00
0
85+
3,598,000
0.00
0
Total
263,435,000
1,518.4
4,000,000
INVASIVE INFECTIONS
<1
3,963,000
5.69
226
1–4
16,219,000
5.69
924
5–14
38,056,000
5.69
2,167
15–24
36,263,000
5.69
2,065
25–34
41,670,000
5.69
2,373
35–44
42,149,000
5.69
2,400
45–54
30,224,000
5.69
1,721
55–64
21,241,000
5.69
1,209
65–74
18,964,000
5.69
1,080
75–84
11,088,000
5.69
631
85+
3,598,000
5.69
205
Total
263,435,000
5.69
15,000
For the purposes of this report, the committee assumed that invasive GAS disease manifests as necrotizing fasciitis (with and without lifetime sequelae) in 10% of cases and toxic shock (lasting 15 days and associated with HUIs of .16 during hospitalization and .58 following hospitalization) for 10% of cases. 80% of the invasive forms of the disease are associated with 2 weeks of illness and HUIs of .62 and .73 for the time spent inpatient and outpatient, respectively. See Table A24–2.
COST INCURRED BY DISEASE
Table A24–3 summarizes the health care costs incurred by GAS infections. For the purposes of the calculations in this report, it was assumed that all pa-
